Researchers at a U.S. biotechnology company are optimistic about a new blood test that they hope can make early-stage cancer diagnosis affordable and accessible globally.
California-based Novelna has shown initial positive results in the test's ability to detect 18 types of cancers.
Ashkan Afshin, the chief executive officer of the company, told Devex that they hope to “make these cancer screenings scalable and affordable for everyone.”